Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$250.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello's partner for Japan Torii Pharmaceutical Co., Ltd reports positive trial results for house dust mite SLIT-tablet


Monday, 10 Mar 2014 03:00am EDT 

Alk Abello A/S:Says its partner for Japan, Torii Pharmaceutical Co., Ltd., has reported positive results from its Phase II/III trial into ALK’s sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite-induced allergic rhinitis (hay fever).Says the trial met its primary efficacy endpoint by showing a significantly lower ‘Total Combined Rhinitis Score’ (TCRS) when compared with patients who received placebo.Says the trial also showed that the treatment was well tolerated and had a favourable safety profile. 

Company Quote

3010.0
27.0 +0.91%
22 Jul 2014